Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications

Sophie Paczesny, Maribel Diaz-Ricart, Enrique Carerras, Kenneth R. Cooke

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed over 40 years ago, this life-saving procedure has been used increasingly for patients with hematologic, metabolic, and malignant diseases. Despite major advances in our understanding of the immunologic processes (both beneficial and injurious) that are associated with HSCT and improvements in supportive and critical care medicine, successful outcomes are still limited by several serious complications. As such, the establishment of effective therapeutic strategies for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. The development of such approaches is fundamentally dependent upon a basic understanding of pathophysiologic mechanisms of disease and also on our ability to successfully translate these insights back to the bedside. This brief review will highlight breakthroughs in translational research endeavors that have paved the way for the development of novel strategies intended to change the standard of care and optimize outcomes for patients in whom allogeneic HSCT offers the only hope for a cure.

Original languageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number1 SUPPL
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Translational Medical Research
Hematopoietic Stem Cell Transplantation
Biomarkers
Transplants
Metabolic Diseases
Critical Care
Standard of Care
Medicine
Therapeutics

Keywords

  • Cytokines
  • Endothelial cell (EC)
  • Graft-versus-host disease (GVHD)
  • Hematopoietic stem cell transplantation (HSCT)
  • Idiopathic pneumonia syndrome (IPS)
  • Inflammation
  • Microvasculature
  • Thrombotic microangiopathy (TMA)
  • Tumor necrosis factor alpha (TNFα)
  • Veno-occlusive disease (VOD)

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications. / Paczesny, Sophie; Diaz-Ricart, Maribel; Carerras, Enrique; Cooke, Kenneth R.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 1 SUPPL, 01.2011.

Research output: Contribution to journalArticle

@article{8b18fadde8624643b9b62040b18a796b,
title = "Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications",
abstract = "In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed over 40 years ago, this life-saving procedure has been used increasingly for patients with hematologic, metabolic, and malignant diseases. Despite major advances in our understanding of the immunologic processes (both beneficial and injurious) that are associated with HSCT and improvements in supportive and critical care medicine, successful outcomes are still limited by several serious complications. As such, the establishment of effective therapeutic strategies for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. The development of such approaches is fundamentally dependent upon a basic understanding of pathophysiologic mechanisms of disease and also on our ability to successfully translate these insights back to the bedside. This brief review will highlight breakthroughs in translational research endeavors that have paved the way for the development of novel strategies intended to change the standard of care and optimize outcomes for patients in whom allogeneic HSCT offers the only hope for a cure.",
keywords = "Cytokines, Endothelial cell (EC), Graft-versus-host disease (GVHD), Hematopoietic stem cell transplantation (HSCT), Idiopathic pneumonia syndrome (IPS), Inflammation, Microvasculature, Thrombotic microangiopathy (TMA), Tumor necrosis factor alpha (TNFα), Veno-occlusive disease (VOD)",
author = "Sophie Paczesny and Maribel Diaz-Ricart and Enrique Carerras and Cooke, {Kenneth R.}",
year = "2011",
month = "1",
doi = "10.1016/j.bbmt.2010.11.025",
language = "English (US)",
volume = "17",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1 SUPPL",

}

TY - JOUR

T1 - Translational Research Efforts in Biomarkers and Biology of Early Transplant-Related Complications

AU - Paczesny, Sophie

AU - Diaz-Ricart, Maribel

AU - Carerras, Enrique

AU - Cooke, Kenneth R.

PY - 2011/1

Y1 - 2011/1

N2 - In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed over 40 years ago, this life-saving procedure has been used increasingly for patients with hematologic, metabolic, and malignant diseases. Despite major advances in our understanding of the immunologic processes (both beneficial and injurious) that are associated with HSCT and improvements in supportive and critical care medicine, successful outcomes are still limited by several serious complications. As such, the establishment of effective therapeutic strategies for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. The development of such approaches is fundamentally dependent upon a basic understanding of pathophysiologic mechanisms of disease and also on our ability to successfully translate these insights back to the bedside. This brief review will highlight breakthroughs in translational research endeavors that have paved the way for the development of novel strategies intended to change the standard of care and optimize outcomes for patients in whom allogeneic HSCT offers the only hope for a cure.

AB - In the time since the first allogeneic hematopoietic stem cell transplantation (HSCT) was performed over 40 years ago, this life-saving procedure has been used increasingly for patients with hematologic, metabolic, and malignant diseases. Despite major advances in our understanding of the immunologic processes (both beneficial and injurious) that are associated with HSCT and improvements in supportive and critical care medicine, successful outcomes are still limited by several serious complications. As such, the establishment of effective therapeutic strategies for these complications will be crucial as increasing numbers of high-risk transplants are performed each year. The development of such approaches is fundamentally dependent upon a basic understanding of pathophysiologic mechanisms of disease and also on our ability to successfully translate these insights back to the bedside. This brief review will highlight breakthroughs in translational research endeavors that have paved the way for the development of novel strategies intended to change the standard of care and optimize outcomes for patients in whom allogeneic HSCT offers the only hope for a cure.

KW - Cytokines

KW - Endothelial cell (EC)

KW - Graft-versus-host disease (GVHD)

KW - Hematopoietic stem cell transplantation (HSCT)

KW - Idiopathic pneumonia syndrome (IPS)

KW - Inflammation

KW - Microvasculature

KW - Thrombotic microangiopathy (TMA)

KW - Tumor necrosis factor alpha (TNFα)

KW - Veno-occlusive disease (VOD)

UR - http://www.scopus.com/inward/record.url?scp=78650668150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650668150&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.11.025

DO - 10.1016/j.bbmt.2010.11.025

M3 - Article

C2 - 21195297

AN - SCOPUS:78650668150

VL - 17

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1 SUPPL

ER -